Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Summary

This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia. Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. These donated stem cells may help destroy cancer cells. Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant may work better in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic lymphocytic leukemia.

Conditions

• B-Cell Prolymphocytic Leukemia
• Hypodiploidy
• Loss of Chromosome 17p
• Plasma Cell Leukemia
• Progression of Multiple Myeloma or Plasma Cell Leukemia
• Recurrent Adult Hodgkin Lymphoma
• Recurrent Adult Non-Hodgkin Lymphoma
• Recurrent Childhood Hodgkin Lymphoma
• Recurrent Childhood Non-Hodgkin Lymphoma
• Recurrent Chronic Lymphocytic Leukemia
• Recurrent Plasma Cell Myeloma
• Recurrent Small Lymphocytic Lymphoma
• Refractory Childhood Hodgkin Lymphoma
• Refractory Chronic Lymphocytic Leukemia
• Refractory Non-Hodgkin Lymphoma
• Refractory Plasma Cell Myeloma
• Refractory Small Lymphocytic Lymphoma
• t(14;16)
• t(4;14)
• T-Cell Prolymphocytic Leukemia
• Waldenstrom Macroglobulinemia

Interventions

PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo donor HCT

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo donor HCT

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous PBSC transplant

PROCEDURE

Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation

Undergo autologous-donor tandem HCT

DRUG

Carmustine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative study

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo donor HCT

DRUG

Tacrolimus

Given IV or PO

RADIATION

Total-Body Irradiation

Undergo TBI

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Fred Hutchinson Cancer Center

  lead OTHER

Principal Investigators

• Mohamed Sorror · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-03-18

Primary Completion

2018-06-30

Completion

2018-06-30

Countries

• United States

Study Locations